Homocysteine excess: Delineating the possible mechanism of neurotoxicity and depression

Fundamental and Clinical Pharmacology

Volumn 29, Issue 6, 2015, Pages 522-528

  Bhatia, Pankaj ^a   Singh, Nirmal ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Depression; Genetic alteration; Homocysteine; Neurotoxicity; Neurotransmitters

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADRENALIN; CYANOCOBALAMIN; CYSTEINE SULFINIC ACID; DOPAMINE; FOLIC ACID; HOMOCYSTEIC ACID; HOMOCYSTEINE; METHIONINE; METHIONINE SYNTHASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; PYRIDOXINE; S ADENOSYLMETHIONINE; CYSTEINE;

DEMETHYLATION; DEPRESSION; DESULFURIZATION; DOPAMINERGIC NERVE CELL; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; MOLECULAR MECHANICS; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; METABOLISM; NEUROTOXICITY SYNDROMES;

CYSTEINE; DEPRESSION; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; NEUROTOXICITY SYNDROMES; S-ADENOSYLMETHIONINE;

EID: 84983151060     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12145     Document Type: Review

References (61)

1. Ingenbleek Y. The Oxidative Stress of Hyperhomocysteinemia Results from Reduced Bioavailability of Sulfur-Containing Reductants. Open Clin. Chem. J. (2011) 4 34-44.
2. Folstein M., Liu T., Peter I. et al. The homocysteine hypothesis of depression. Am. J. Psychiatry (2007) 164 861-867.
3. Stanger O., Fowler B., Piertzik K. et al. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev. Neurother. (2009) 9 1393-1412.
4. Wesseling S., Koeners M.P., Joles J.A. Taurine: Red Bull or Red Herring? Hypertension (2009) 53 909-911.
5. Bleich S., Degner D., Wiltfang J. et al. Elevated homocysteine levels in alcohol withdrawal. Alcohol Alcohol. (2000) 35 351-354.
6. Obeid R., Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. (2006) 580 2994-3005.
7. Ebesunun M.O., Eruvulobi H.U., Olagunju T. et al. Elevated plasma homocysteine in association with decreased vitamin B12, folate, serotonin, lipids and lipoproteins in depressed patients. Afr. J. Psychiatry. (Johannesbg) (2012) 15 25-29.
8. Botez M.I., Young S.N., Bachevalier J. et al. Effect of folic-acid and vitamin-B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal-fluid. Ann. Neurol. (1982) 12 479-484.
9. Bottiglieri T., Laundy M., Crellin R. et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry (2000) 69 228-232.
10. Blount B.C., Mack M.M., Wehr C.M. et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc. Natl Acad. Sci. (1997) 94 3290-3295.
11. Clarke R., Lewington S., Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int. (2003) 63 S131-S133.
12. Wolters M., Strohle A., Hahn A. Age-associated changes in the metabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis and pathophysiological consequences. Z. Gerontol. Geriatr. (2004) 37 109-135.
13. Romagnuolo J., Fedorak R.N., Dias V.C. et al. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am. J. Gastroenterol. (2001) 96 2143-2149.
14. Nilsson S.E., Takkinen S., Johansson B. et al. Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people. Eur. J. Clin. Pharmacol. (2004) 60 45-49.
15. Westphal S., Rading A., Luley C. et al. Antihypertensive treatment and homocysteine concentrations. Metabolism (2003) 52 261-263.
16. Papakostas G.I., Petersen T., Mischoulon D. et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. J. Clin. Psychiatry (2004) 65 1090-1095.
17. Eichholzer M., Tonz O., Zimmermann R. Folic acid: a public health challenge. Lancet (2006) 367 1352-1361.
18. Brown A.S., Bottiglieri T., Schaefer C.A. et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch. Gen. Psychiatry (2007) 64 31-39.
19. Miller A.L. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern. Med. Rev. (2008) 13 216-226.
20. Gariballa S. Testing homocysteine-induced neurotransmitter deficiency and depression of mood hypothesis in clinical practice. Age Ageing (2011) 40 702-705.
21. Faraci F.M., Lentz S.R. Hyperhomocysteinemia, oxidative stress and cerebral vascular dysfunction. Stroke (2004) 35 345-347.
22. Goyette P., Sumner J.S., Milos R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat. Genet. (1994) 7 195-200.
23. Lea R., Colson N., Quinlan S. et al. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet. Genomics (2009) 19 422-428.
24. Frosst P., Blom H.J., Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. (1995) 10 111-113.
25. Liu A., Menon S., Colson N.J. et al. Analysis of the MTHFR C677T variant with migraine phenotypes. BMC Res. Notes (2010) 3 213.
26. Markus H.S., Ali N., Swaminathan R. et al. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke (1997) 28 1739-1743.
27. Kirke P.N., Mills J.L., Molloy A.M. et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ (2004) 328 1535-1536.
28. Kim J.M., Kim S.W., Shin I.S. et al. Folate, vitamin B12, and homocysteine as risk factors for cognitive decline in the elderly. Psychiatry Invest. (2008) 5 36-40.
29. Mattson M.P., Kruman I.I., Duan W. Folic acid and homocysteine in age-related disease. Ageing Res. Rev. (2002) 1 95-111.
30. Szolnoki Z., Somogyvari F., Kondacs A. et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J. Neurol. Neurosurg. Psychiatry (2003) 74 1615-1620.
31. Schimke R.N., McKusick V.A., Huang T. et al. Homocystinuria: studies of 20 families with 38 affected members. JAMA (1965) 193 711-719.
32. Boldyrev A. Molecular mechanisms of homocysteine toxicity and possible protection against hyperhomocysteinemia. Recent Adv. Nutr. Prevent. Alzheimer's Dis. (2010) 127-143. ISBN: 978-81-7895-470-7.
33. Abramov A.Y., Scorziello A., Duchen M.R. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J. Neurosci. (2007) 27 1129-1138.
34. McCully K.S. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann. Clin. Lab. Sci. (2009) 39 219-232.
35. Machado F.R., Ferreira A.G., da Cunha A.A. et al. Homocysteine alters glutamate uptake and Na+, K + -ATPase activity and oxidative status in rats hippocampus: protection by vitamin C. Metab. Brain Dis. (2011) 26 61-67.
36. Lipton S.A., Kim W.K., Choi Y.B. et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl Acad. Sci. (1997) 94 5923-5928.
37. Lutz U.C. Alterations in homocysteine metabolism among alcohol dependent patients-clinical, pathobiochemical and genetic aspects. Curr. Drug Abuse Rev. (2008) 1 47-55.
38. Matte C., Mussulini B.H.M., dos Santos T.M. et al. Hyperhomocysteinemia reduces glutamate uptake in parietal cortex of rats. Int. J. Dev. Neurosci. (2010) 28 183-187.
39. Reynolds E.H. Methylfolate as adjunctive treatment in depression. Am. J. Psychiatry (2013) 170 560.
40. Carvalho A.F., Miskowiak K.K., Hyphantis T.N. et al. Cognitive dysfunction in depression-pathophysiology and novel targets. CNS Neurol. Disord. Drug Targets (2014) 13 1819-1835.
41. Young S.N. Folate and depression-a neglected problem. J. Psychiatry Neurosci. (2007) 32 80.
42. Fava M., Borus J.S., Alpert J.E. et al. Folate, vitamin B12, and homocysteine in major depressive disorder. Am. J. Psychiatry (1997) 154 426-428.
43. Nabi H., Bochud M., Glaus J. et al. Association of serum homocysteine with major depressive disorder: results from a large population-based study. Psychoneuroendocrinology (2013) 38 2309-2318.
44. Duan W., Ladenheim B., Cutler R.G. et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. (2002) 80 101-110.
45. Lee E.S.Y., Chen H., Soliman K.F. et al. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology (2005) 26 361-371.
46. Zhao W.Q., Williams Z., Shepherd K.R. et al. S-adenosyl-methionine-induced apoptosis in PC12 cells. J. Neurosci. Res. (2002) 69 519-529.
47. Linnebank M., Lutz H., Jarre E. et al. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol. Dis. (2006) 23 725-730.
48. Forti P., Rietti E., Pisacane N. et al. Blood homocysteine and risk of depression in the elderly. Arch. Gerontol. Geriatr. (2010) 51 21-25.
49. Curcio M., Catto E., Stramentinoli G. et al. Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Prog. Neuropsychopharmacol. (1978) 2 65-71.
50. Levkovitz Y., Alpert J.E., Brintz C.E. et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur. Psychiatry (2012) 27 518-521.
51. Hirata F., Axelrod J. Phospholipid methylation and biological signal transmission. Science (1980) 209 1082-1090.
52. Tchantchou F., Graves M., Falcone D. et al. S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J. Alzheimers Dis. (2008) 14 323-328.
53. Botez M.I., Young S.N. Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain (1991) 114 333-348.
54. Botez M.I., Young S.N., Bachevalier J. et al. Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature (1979) 278 182-183.
55. Morris M.S., Fava M., Jacques P.F. et al. Depression and folate status in the US population. Psychother. Psychosom. (2003) 72 80-87.
56. Duthie S.J., Whalley L.J., Collins A.R. et al. Homocysteine, B vitamin status, and cognitive function in the elderly. Am. J. Clin. Nutr. (2002) 75 908-913.
57. Riggs K.M., Spiro A.I.I.I., Tucker K. et al. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr (1996) 63 306-314.
58. Chen C.S., Tsai J.C., Tsang H.Y. et al. Homocysteine levels, MTHFR C677T genotype, and MRI hyperintensities in late-onset major depressive disorder. Am. J. Geriatr. Psychiatry (2005) 13 869-875.
59. Hickie I., Scott E. Late-onset depressive disorders: a preventable variant of cerebrovascular disease? Psychol. Med. (1998) 28 1007-1013.
60. Narayan S.K., Verman A., Kattimani S. et al. Plasma homocysteine levels in depression and schizophrenia in South Indian Tamilian population. Indian J. Psychiatry(2014) 56 46.
61. Almeida O.P., McCaul K., Hankey G.J. et al. Homocysteine and depression in later life. Arch. Gen. Psychiatry (2008) 65 1286-1294.